18.09.2021 | permalink
Summary
New data concerning chromothripsis may affect the long-term outlook of companies such as Crispr Therapeutics.
The long-term impact on health of gene editing may not be known until around 2040.
Given the uncertain outlook, investors may be wise to re-evaluate their positions in companies employing DNA double strand breaks to edit the genome.
